Myosteatosis, cognition and blood biomarkers of alzheimer's disease in persons of african ancestry

Active Grant Awarded

Award ID
R01AG077474
Recipient
Awarding agency
Obligated
$1,257,655

Award facts

Assistance listing
93.866 Aging Research
Completion date 26% complete
Place of performance
Pennsylvania, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Grant R01AG077474 to the University of Pittsburgh – Of the Commonwealth System of Higher Education, with $1.257655 million obligated on June 3, 2026, under the Aging Research program (CFDA 93.866). The award funds research testing whether myosteatosis (fat within muscle) and myokines influence clinical and biological markers of Alzheimer's disease and related dementias late in life among persons of African ancestry. Aim 1 addresses myosteatosis and Aim 2 addresses myokines, and the work tests whether these effects differ by sex and operate independently of adipokines and other adiposity measures. The project builds on the recipient's NIH-funded, 20-plus-year longitudinal studies in Tobago, which enroll approximately 4,000 participants. The Regents of the University of Minnesota, operating through its Office of Sponsored Projects Administration, is the award's subrecipient under subaward R01AG077474-AWD00012581, dated November 9, 2026. The subrecipient performs testing on lipid panel, glucose, insulin, hsCRP, IL-6, leptin, adiponectin, irisin, myostatin, BDNF, Cathepsin-B, and leukemia inhibitory factor biomarkers. The period of performance ends March 31, 2028, and the place of performance is Pennsylvania, USA. The Aging Research program supports biomedical, social, and behavioral research on aging and its diseases, with the National Institute on Aging emphasizing prevention and treatment of Alzheimer's disease and related dementias.

Description

Abstract
Persons of african ancestry (PAA) have higher rates of alzheimer's disease and related dementias (ADRD) and higher rates of adiposity, compared to other races. While overall adiposity and visceral FAT are known risk factors for cognitive impairment and ADRD, emerging evidence by US and others suggests that FAT in muscle (MYOSTEATOSIS) has independent negative effects on cognition and brain health among PAA. Since MYOSTEATOSIS is greater in PAA compared to others, we propose that MYOSTEATOSIS may be a novel risk factor with special relevance for ADRD in PAA. Compared to overall or visceral adiposity, MYOSTEATOSIS could be more harmful to the brain; while adipose tissue in muscle and elsewhere releases adipokines with pro-inflammatory effects, MYOSTEATOSIS also damages muscle and impairs release of myokines, which are largely beneficial to metabolism and neural health. Since ADRD develops slowly, midlife and subsequent increase in MYOSTEATOSIS over time may influence later brain health. Our overarching hypothesis is that MYOSTEATOSIS in PAA harms brain health in older age, in part, by compromising myokine homeostasis. Unknown, but key to establishing the foundation for this novel source of risk, is whether MYOSTEATOSIS (aim 1) and myokines (aim 2) influence clinical and biological markers of ADRD late in life, and whether these effects are stronger and independent of adipokines, other adiposity (e.g. total, regional). All hypotheses account for risk factors for poor cognition; especially, but not only, genetic factors (APOE4), and adiposity-related conditions (diabetes, hypertension, sedentary behavior, poor sleep). Since SEX affects the prevalence of ADRD and MYOSTEATOSIS, we test whether associations vary by SEX. We build on our ongoing NIH-funded 20+year longitudinal studies of PAA in the tobago caribbean region (N~4,000). For this tobago brain study, we will recruit 1000 of them who are aged 65+, with existing midlife measures of: MYOSTEATOSIS, other adiposity, demographics, medical and reproductive history, circulating biomarkers of metabolism (homa-IR, lipids, etc), subclinical vascular measures, and blood biorepository. We will repeat these measures, and newly add detailed neuropsychological tests, plasma levels of ADRD biomarkers, and adipokines. We measure myokines both at mid-life (using our existing biorepository) and at the proposed new exam. This study provides an unprecedented opportunity to examine the influence of midlife MYOSTEATOSIS and related myokines on brain health in a minority population using a cost-effective study design and existing NIH investments. We expect to determine the extent to which MYOSTEATOSIS and specific MYOSTEATOSIS-related myokine patterns contribute independently to cognitive function and biomarkers of ADRD in PAA. Our findings could lead to novel subgroup-targeted, muscle FAT-specific interventions to reduce ADRD risk in PAA.

Subawards

Subrecipient Amount Awarded
Regents Of The University Of Minnesota UMN is responsible for performing testing on agreed-upon biomarkers to include the following analyses: Lipid panel, glucose, insulin, hsCRP, IL-6, Leptin,… $408,516

Quick answers

Who received award R01AG077474?

R01AG077474 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Institute on Aging (National Institutes of Health) on June 3, 2026.

How much is award R01AG077474 worth?

$1,257,655 has been obligated on R01AG077474.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award